Cite
HARVARD Citation
Levy, M. et al. (2021). Comparison of incidence/occurrence of cardiovascular events between ponatinib vs bosutinib among patients with at least one prior line of tyrosine kinase inhibitors in chronic myeloid leukemia in a community setting in the United States. Cancer treatment and research communications. p. . [Online].